Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2005

View Archived Issues

Zadaxin shows dose-dependent response in combination with DTIC with and without low-dose interferon

Increased GABA-A alpha1 subunit reduced status epilepticus in rats by 50%

Passiflora incarnata might contain anticonvulsive ingredients

Update on clinical study of tefibazumab

Clinical study of STA-5326 for psoriasis

Novartis to consider acquiring Berna Biotech

Innogenetics reviews diagnostics and therapeutics businesses

Advisory Committee reviews Zostavax

Eisai resubmits corrected Aricept sNDA

FDA lifts clinical hold on phase I study of CB-001

Voluntary suspension of sales, marketing and distribution of NeutroSpec

FDA rules BioThrax is safe and effective to prevent anthrax

Phase III study of tifacogin in severe CAP cleared to continue

Ethics approval for study of MPL-TLB100

Results from cell line study of Factor 5A in multiple myeloma

Urocortin 2 demonstrates positive effects on cardiac output and blood pressure

Remodulin effective in improving six-minute walk distance in PAH patients

No significant increase in time to neurologic progression in Xcytrin study

Astellas discloses data on a novel parenteral cephalosporin

BC-2901: Novel broad-spectrum cephem-azomethine

WQ-3335: Novel fluoroquinolone with high efficacy against mutated S. pneumoniae

BLX-1060 -- potential for IBD

New treatments for urological disorders claimed in recent Tanabe Seiyaku and Eisai patents

New antiinfective compounds revealed

Prostanoid EP4 agonists for ocular disorders emerge from Merck Frosst R&D

TLK-199 induces responses in myelodysplastic syndrome patients

CEP-701 enhances chemotherapy for FLT3 mutation acute myelogenous leukemia

New data on AMG-531 in immune thrombocytopenic purpura reported

SGN-30 evaluated in phase II studies in lymphoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...